In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and BOSTON & SHANGHAI & CAMBRIDGE, Mass., January 10, 2025--Vertex Pharmaceuticals ...

International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals’ Death Cross signals a bearish trend as shares fall below all critical moving averages. Clinical trial disappointments and technical sell signals pressure VRTX ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $468.09, demonstrating a +0.94% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.38% gain on the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...